KP
BIIB icon

Keel Point’s Biogen BIIB Stock Holding History

Keel Point’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,292
Closed -$227K – 487
2025
Q4 		$227K Buy
+1,292
New +$211K 0.01% 475

Other funds holding BIIB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Keel Point's BIIB Position: Q1 2026 in Review

Keel Point sold out of Biogen (BIIB) in Q1 2026, closing a stake of 1,292 shares — an estimated $227K sold.

Keel Point first reported a position in BIIB in Q4 2025 and held it in 1 quarter. The position peaked at $227K in Q4 2025. 1,002 funds tracked by Wall St. Rank hold BIIB as of Q1 2026.

  • Keel Point reported no remaining Biogen position as of Q1 2026 after selling out during the quarter.
  • Keel Point sold 1,292 Biogen shares in Q1 2026, an estimated $227K.
  • Keel Point first reported a position in Biogen in Q4 2025 and held it in 1 quarter.
  • Keel Point's Biogen position peaked at $227K in Q4 2025.
  • 1,002 funds tracked by Wall St. Rank held Biogen as of Q1 2026.

Based on Keel Point's 13F filing for Q1 2026, filed 1 Jun 2026.